cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
About this study
The EpiCORE study aims to identify cfDNA-based epigenetic markers predictive of response to first-line chemotherapy (FOLFOX or FOLFIRI) in metastatic colorectal cancer (mCRC). By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to establish a non-invasive biomarker panel capable of distinguishing responders from non-responders.
- Condition
- CRC (Colorectal Cancer)
- Tested
- cfDNA 5mC/5hmC Sequencing (EpiCORE Discovery Phase), EpiCORE Assay (Targeted Sequencing / qPCR Validation)
- Sponsor
- City of Hope Medical Center
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Study condition: CRC (Colorectal Cancer)
- Histologically confirmed metastatic colorectal adenocarcinoma (mCRC).
- Received first-line chemotherapy (FOLFOX or FOLFIRI).
- Availability of pre-treatment serum or plasma samples for cfDNA 5mC/5hmC analysis.
- Documented radiologic or clinical response evaluation (RECIST 1.1 or PFS-based).
- RAS/BRAF mutation status available.
Exclusion 4
- Inadequate cfDNA yield or poor DNA quality.
- Non-adenocarcinoma histology.
- Active inflammatory or autoimmune disease that may alter cfDNA methylation.
- Concomitant malignancy requiring systemic therapy.
Where
1 site, 1 recruiting
City of Hope Medical Center
Duarte, California, United States
Contact
-
Ajay Goel, PhD
6263598111 ajgoel@coh.org
Potential match only. Final eligibility is determined by the study team.